Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 8:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Telangiectasia Clear all
Not yet recruiting Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Ductal Carcinoma, Estrogen-receptor-positive Breast Cancer, Atypical Lobular Hyperplasia, BRCA2 Mutation, CHEK2 Gene Mutation, Ataxia Telangiectasia Mutated Gene Mutation
Interventions
Exemestane, Tamoxifen
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 29, 2026 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Vascular Lesion
Interventions
Tandem 532/1064 nm Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced May 21, 2026, 8:38 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Ataxia Telangiectasia Louis-Bar, Ataxia Telangiectasia in Children, Ataxia Telangiectasia
Interventions
MBM-01
Drug
Lead sponsor
Matrix Biomed, Inc.
Industry
Eligibility
4 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 16, 2021 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Erythematotelangiectatic Rosacea, Papulopustular Rosacea
Interventions
Apremilast
Drug
Lead sponsor
Julian M. Mackay-Wiggan
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 12, 2016 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced May 21, 2026, 8:38 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Ataxia-Telangiectasia (A-T)
Interventions
A-T iPS cell line, Carrier patients iPS cell line
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
3 Years to 100 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 18, 2019 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Macular Telangiectasia
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
NT-501 implant
Biological
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced May 21, 2026, 8:38 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Interventions
Data collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced May 21, 2026, 8:38 PM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Pomalidomide
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
Not listed
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
11
States / cities
San Diego, California • San Francisco, California • Gainesville, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced May 21, 2026, 8:38 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Breast Cancer, Radiation-Induced Telangiectasias
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 6, 2018 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Bevacizumab
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 5, 2019 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 4 Interventional Results available
View directory record Official record
Conditions
Epistaxis
Interventions
Doxycycline, Placebo
Drug · Other
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced May 21, 2026, 8:38 PM EDT
Not listed Phase 2 Interventional
View directory record Official record
Conditions
Macular Telangiectasia Type 2
Interventions
Serine, Fenofibrate
Dietary Supplement · Drug
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
8
States / cities
Atlanta, Georgia • Ann Arbor, Michigan • Cleveland, Ohio + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced May 21, 2026, 8:38 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Not listed
Lead sponsor
Unity Health Toronto
Other
Eligibility
Not listed
Enrollment
2,272 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2025
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Angeles, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced May 21, 2026, 8:38 PM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Metastatic Cancer
Interventions
Palliative radiotherapy
Radiation
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
7
States / cities
Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced May 21, 2026, 8:38 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
Not listed
Lead sponsor
Quince Therapeutics S.p.A.
Industry
Eligibility
6 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced May 21, 2026, 8:38 PM EDT
Completed No phase listed Observational
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Ultra-low dose chest CT
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Feraheme MRI/MRA
Procedure
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jan 24, 2019 · Synced May 21, 2026, 8:38 PM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Macular Telangiectasia
Interventions
577-nm PASCAL laser
Device
Lead sponsor
The Lowy Medical Research Institute Limited
Other
Eligibility
21 Years to 79 Years
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced May 21, 2026, 8:38 PM EDT
Completed No phase listed Observational Accepts healthy volunteers
View directory record Official record
Conditions
All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis, Asthma, Atopic Dermatitis Eczema, Beta Thalassemia, Bipolar Disorder, Breast Cancer, Celiac Disease, Cervical Cancer, Chronic Inflammatory Demyelinating Polyneuropathy, Chronic Kidney Diseases, Chronic Obstructive Pulmonary Disease, Colon Cancer, Colorectal Cancer, Crohn's Disease, Cystic Fibrosis, Depression, Diabetes Mellitus, Duchenne Muscular Dystrophy, Endometriosis, Epilepsy, Facioscapulohumeral Muscular Dystrophy, G6PD Deficiency, General Anxiety Disorder, Hepatitis B, Hereditary Hemorrhagic Telangiectasia, HIV/AIDS, Human Papilloma Virus, Huntington's Disease, Idiopathic Thrombocytopenic Purpura, Insomnia, Kidney Cancer, Leukemia, Lung Cancer, Lupus Nephritis, Lymphoma, Melanoma, Multiple Myeloma, Multiple Sclerosis, Myositis, Myotonic Dystrophy, Ovarian Cancer, Pancreatic Cancer, Parkinson's Disease, Polycystic Kidney Diseases, Prostate Cancer, Psoriasis, Psoriatic Arthritis, Rosacea, Scleroderma, Sickle Cell Anemia, Sickle Cell Trait, Sjogren's Syndrome, Skin Cancer, Spinal Muscular Atrophy, Systemic Lupus Erythematosus, Thrombotic Thrombocytopenic Purpura, Trisomy 21, Ulcerative Colitis
Interventions
Not listed
Lead sponsor
Sanguine Biosciences
Industry
Eligibility
18 Years to 100 Years
Enrollment
17,667 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2024
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2024 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Telangiectasia, Hereditary Hemorrhagic, Epistaxis
Interventions
Sterile saline, Bevacizumab, Estriol, Tranexamic Acid
Drug
Lead sponsor
James Gossage
Other
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
6
States / cities
Los Angeles, California • Augusta, Georgia • Baltimore, Maryland + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2018 · Synced May 21, 2026, 8:38 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Neovascularization
Interventions
Ranibizumab
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced May 21, 2026, 8:38 PM EDT